Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Lakeview Dairy Farms
WARNING LETTER
•Lakeview Dairy Farms•February 11, 2008

FDA WARNING_LETTER - Lakeview Dairy Farms - February 11, 2008

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

An FDA inspection on January 29 and February 11, 2008, at a dairy operation in Bakersfield, California, revealed multiple violations. A dairy cow consigned for slaughter on July 23, 2007, was found to have Flunixin residues in liver tissue at 0.448 ppm and muscle tissue at 0.063 ppm, exceeding the established tolerances of 0.125 ppm and 0.025 ppm, respectively. This rendered the animal adulterated under sections 402(a)(2)(C)(ii) and 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act).

The operation lacked an adequate system to prevent medicated animals with harmful drug residues from entering the food supply, specifically failing to maintain complete treatment records. This also constitutes adulteration under section 402(a)(4) of the Act.

Furthermore, the new animal drug Flunixin Meglumine Injectable Solution was adulterated under section 501(a)(5) of the Act due to extralabel use not conforming to approved labeling and 21 C.F.R. Part 530. Specifically, the drug was administered via intramuscular injection instead of the veterinarian's prescribed intravenous route, violating 21 C.F.R. 530.11(a), and resulted

Company
Lakeview Dairy Farms
Inspection Date
February 11, 2008
Product Type
Drugs
Office
San Francisco District Office
People
  • Barbara J. Cassens (Director )
  • Asif Mann (California Department of Public Health)
  • Neal Westgerdes
Open in Dashboard

ID · df2ac45c-d6e0-434d-985c-8e813a26d1b0

Violation Codes8
21 U.S.C. 342(a)(2)(C)(ii)21 U.S.C. 342(a)(4)21 U.S.C. 360b(a)21 U.S.C. 351(a)(5)21 U.S.C. 360b(a)(4)21 U.S.C. 360b(a)(5)21 CFR 530.11(a)21 CFR 530.11(d)

Full citation text and observation details available on the Dashboard.

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.